Rexahn (RNN) Rips Following Positive Archexin Phase II Data
Tweet
Share
E-mail
Get Alerts RNN Hot Sheet
Join SI Premium – FREE
Shares of Rexahn Pharmaceuticals (AMEX: RNN) are ripping higher in premarket action Tuesday, following strong data issued earlier from its Phase II clinical study of Archexin.
According to Rexahn, "the study demonstrated that treatment with Archexin in combination with gemcitabine provided a median survival of 9.1 months compared to the historical survival data of 5.65 months (Burris et al., 1997, J. Clin Oncol 15:2403) for standard single agent gemcitabine therapy."
Shares are up nearly 40 percent in early trading.
According to Rexahn, "the study demonstrated that treatment with Archexin in combination with gemcitabine provided a median survival of 9.1 months compared to the historical survival data of 5.65 months (Burris et al., 1997, J. Clin Oncol 15:2403) for standard single agent gemcitabine therapy."
Shares are up nearly 40 percent in early trading.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Dollar Tree (DLTR) falls 5.6% after Director filed notice to sell $133.1M worth of shares
- Qualcomm expects $40bn in non-handset revenue by fiscal 2029
- Kioxia Plans To List Adrs In Us Around April Or May 2027 - Bloomberg
Create E-mail Alert Related Categories
FDA, Momentum Movers, Trader TalkSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
